Pawel Dyk1, Ashley Weiner1, Shahed Badiyan1, Robert Myerson1, Parag Parikh1, Jeffrey Olsen2. 1. Department of Radiation Oncology, Washington University School of Medicine, St Louis, Missouri. 2. Department of Radiation Oncology, Washington University School of Medicine, St Louis, Missouri. Electronic address: jolsen@radonc.wustl.edu.
Abstract
PURPOSE: The purpose of this study was to evaluate liver function after high-dose liver stereotactic body radiation therapy (SBRT) in the treatment of metastatic and primary malignancies of the liver using the Child-Pugh score classification system. METHODS AND MATERIALS: This was a retrospective analysis of 46 patients treated with SBRT for metastatic and primary malignancies of the liver. Patient, disease, prior treatment, and SBRT dosimetric factors were analyzed to correlate with decline in Child-Pugh class after liver SBRT. RESULTS: Median follow-up was 11.0 months for patients alive at last follow-up. Twenty-three patients (50%) had primary liver malignancies. Median delivered dose was 55 Gy in 5 fractions (range, 36-60 Gy in 3-6 fractions) to 1 lesion (range, 1-4 lesions) measuring 4.0 cm (range, 1.3-12.4 cm). Forty-one patients (89%) received ≥50 Gy in 3 to 6 fractions. Child-Pugh score classification was A in 42 patients (91%). Seven patients (15%) received adjuvant chemotherapy or targeted therapy. Twenty-nine patients (63%) experienced an intrahepatic recurrence after treatment. Ten patients (22%) experienced a decline in Child-Pugh class at a median of 1.6 months (range, 0.2-6 months). Eighty percent experienced a one-category decline. Only the V20, V25, V30, and V50 were correlated with decline in Child-Pugh class on univariate analysis, with V25 being most significant (P = .027). A V25 >32% was associated with a 42% incidence of Child-Pugh class decline compared with 9% for V25 ≤32 (P = .029). For primary liver malignancies, a V25 >36% was associated with a 4-fold increase in the incidence of Child-Pugh class decline (60% vs 15%, P = .021). CONCLUSIONS: Approximately one-quarter of patients experience a decline in Child-Pugh class after high-dose liver SBRT. The V25 may be an important dosimetric parameter predicting decline in liver function after treatment.
PURPOSE: The purpose of this study was to evaluate liver function after high-dose liver stereotactic body radiation therapy (SBRT) in the treatment of metastatic and primary malignancies of the liver using the Child-Pugh score classification system. METHODS AND MATERIALS: This was a retrospective analysis of 46 patients treated with SBRT for metastatic and primary malignancies of the liver. Patient, disease, prior treatment, and SBRT dosimetric factors were analyzed to correlate with decline in Child-Pugh class after liver SBRT. RESULTS: Median follow-up was 11.0 months for patients alive at last follow-up. Twenty-three patients (50%) had primary liver malignancies. Median delivered dose was 55 Gy in 5 fractions (range, 36-60 Gy in 3-6 fractions) to 1 lesion (range, 1-4 lesions) measuring 4.0 cm (range, 1.3-12.4 cm). Forty-one patients (89%) received ≥50 Gy in 3 to 6 fractions. Child-Pugh score classification was A in 42 patients (91%). Seven patients (15%) received adjuvant chemotherapy or targeted therapy. Twenty-nine patients (63%) experienced an intrahepatic recurrence after treatment. Ten patients (22%) experienced a decline in Child-Pugh class at a median of 1.6 months (range, 0.2-6 months). Eighty percent experienced a one-category decline. Only the V20, V25, V30, and V50 were correlated with decline in Child-Pugh class on univariate analysis, with V25 being most significant (P = .027). A V25 >32% was associated with a 42% incidence of Child-Pugh class decline compared with 9% for V25 ≤32 (P = .029). For primary liver malignancies, a V25 >36% was associated with a 4-fold increase in the incidence of Child-Pugh class decline (60% vs 15%, P = .021). CONCLUSIONS: Approximately one-quarter of patients experience a decline in Child-Pugh class after high-dose liver SBRT. The V25 may be an important dosimetric parameter predicting decline in liver function after treatment.
Authors: Krithika Suresh; Dawn Owen; Latifa Bazzi; William Jackson; Randall K Ten Haken; Kyle Cuneo; Mary Feng; Theodore S Lawrence; Matthew J Schipper Journal: Int J Radiat Oncol Biol Phys Date: 2017-09-22 Impact factor: 7.038
Authors: Stephanie K Schaub; Pehr E Hartvigson; Michael I Lock; Morten Høyer; Thomas B Brunner; Higinia R Cardenes; Laura A Dawson; Edward Y Kim; Nina A Mayr; Simon S Lo; Smith Apisarnthanarax Journal: Technol Cancer Res Treat Date: 2018-01-01
Authors: Trey C Mullikin; Kay M Pepin; Jaden E Evans; Sudhakar K Venkatesh; Richard L Ehman; Kenneth W Merrell; Michael G Haddock; William S Harmsen; Michael G Herman; Christopher L Hallemeier Journal: Adv Radiat Oncol Date: 2021-09-09
Authors: Berardino De Bari; Thomas Breuneval; Michele Zeverino; Sarah Godin; Letizia Deantonio; Christine Geldhof; Jean Bourhis; Nicklaus Schaefer; Raphaël Moeckli; John Prior; Mahmut Ozsahin Journal: PLoS One Date: 2018-10-10 Impact factor: 3.240
Authors: Stephen A Rosenberg; Lauren E Henke; Narek Shaverdian; Kathryn Mittauer; Andrzej P Wojcieszynski; Craig R Hullett; Mitchell Kamrava; James Lamb; Minsong Cao; Olga L Green; Rojano Kashani; Bhudatt Paliwal; John Bayouth; Paul M Harari; Jeffrey R Olsen; Percy Lee; Parag J Parikh; Michael Bassetti Journal: Adv Radiat Oncol Date: 2018-08-23